Randomized, multicenter, double-blind, placebo-controlled, parallel-group Phase III study to investigate the efficacy, safety, and tolerability of 2 different doses of IgPro20 (subcutaneous immunoglobulin) for the treatment
|Effective start/end date||1/1/14 → 4/30/18|
- CSL BEHRING GMBH
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.